# Pharmacological intervention of Chinese medicine via regulating ferroptosis in gastric cancer

**Authors:** Hongchen Zhang, Xiaoxue Du, Jian Chen, Linhao Xu

PMC · DOI: 10.1186/s13020-025-01314-8 · Chinese Medicine · 2026-01-12

## TL;DR

This paper reviews how Chinese medicine can treat gastric cancer by triggering a type of cell death called ferroptosis, which could improve patient outcomes and quality of life.

## Contribution

The paper systematically reviews how traditional Chinese medicine activates ferroptosis pathways to combat gastric cancer drug resistance.

## Key findings

- TCM formulations can prolong survival and reduce adverse reactions in gastric cancer patients.
- Multiple signaling pathways like Wnt/β-catenin and PI3K/AKT/mTOR regulate ferroptosis in GC cells.
- Preclinical studies show TCM compounds can ameliorate GC progression by inducing ferroptosis.

## Abstract

Gastric cancer (GC) is the second most frequently diagnosed malignancy, as well as the second most common cause of cancer-related deaths in China. Drug resistance is a major factor that limits the efficacy of GC chemotherapy. Given the increased resistance of GC cells to ferroptosis, activating the ferroptotic pathways has emerged as a promising therapeutic strategy against GC. This review summarizes the pathways involved in ferroptosis resistance in GC cells and the mechanisms underlying the therapeutic effects of herbal formulae and their bioactive compounds, with particular emphasis on ferroptosis. Multiple signaling pathways are implicated in regulating ferroptosis in GC cells, including the Wnt/β-catenin, PI3K/AKT/mTOR, TGF-β1/Smad, NF-κB, and Hippo pathways. According to previous clinical trials, traditional Chinese medicine (TCM) formulations can prolong the survival or increase survival chances in patients with GC, and reduce adverse reactions, thereby improving the quality of life. Finally, preclinical studies have shown TCMs and their bioactive compounds can ameliorate GC progression by triggering ferroptosis. Despite these beneficial effects on patients with GC, the underlying molecular mechanisms of TCM in GC have not been fully elucidated yet, and there are also some crucial shortcomings in the current studies. Therefore, further clinical trials and experimental studies are required to deepen our understanding of the mechanisms for activating ferroptosis in GC cells through TCM.

## Linked entities

- **Diseases:** gastric cancer (MONDO:0001056)

## Full-text entities

- **Genes:** NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, CTNNB1 (catenin beta 1) [NCBI Gene 1499] {aka CTNNB, EVR7, MRD19, NEDSDV, armadillo}
- **Diseases:** GC (MESH:D013274), cancer (MESH:D009369)
- **Chemicals:** Chinese medicine (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12794327/full.md

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12794327/full.md

---
Source: https://tomesphere.com/paper/PMC12794327